Investors

Investors backing precision medicine companies are betting on infrastructure that takes years to build and decisions that have to land before the bid closes. Commercial due diligence on tools and Dx targets, investor narrative for portfolio companies preparing financings or IPOs, post-investment growth strategy as a thesis meets the market — these are the decisions where the gap between a good investment and a great one usually sits in how well the underlying category dynamics are understood.